SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

August 20, 2026 - 01:00

Sera Prognostics Inc., a company focused on improving maternal and neonatal health through advanced pregnancy biomarker testing, has announced the appointment of Scott Gleason as its new Chief Financial Officer. The appointment is set to take effect on August 31, 2026.

Gleason brings extensive experience in financial leadership within the healthcare and diagnostics sectors. In his new role, he will oversee the company's financial strategy, capital allocation, and investor relations as Sera Prognostics continues to expand its commercial footprint and advance its pipeline of pregnancy-related diagnostic tools.

The company, known for its work in providing innovative biomarker information to physicians and expectant mothers, has been building momentum in the prenatal testing space. Its flagship product aims to identify risks for preterm birth and other complications earlier in pregnancy, which could lead to better outcomes for both mothers and babies.

The outgoing CFO will remain with the company during the transition period to ensure a smooth handover of responsibilities. Sera Prognostics leadership expressed confidence in Gleason's ability to drive financial growth and support the company's long-term mission. The announcement comes as the firm continues to invest in clinical studies and product development, positioning itself for what it hopes will be a period of significant market adoption.